PDCD1 and neoplasm: A multi-center open-label, non-randomized phase 2 study (PRIMMO), in patients with metastatic or recurrent CC, endometrial carcinoma, or uterine sarcoma, evaluated the combination of PD-1 blockade (pembrolizumab), radiation (3x8 Gy in 48 h-intervals) and repurposed compounds (i.e. drugs approved for another indication) with (immune) modulating properties (vitamin D, aspirin, lansoprazole, a proton-pump inhibitor, cyclophosphamide and curcumin) aimed at targeting TME and promoting anti-tumor immunity (63).